NOMURA HOLDINGS INC-SPON ADR (NMR)
US65535H2085 - ADR
Taking everything into account, NMR scores 3 out of 10 in our fundamental rating. NMR was compared to 207 industry peers in the Capital Markets industry. NMR has a bad profitability rating. Also its financial health evaluation is rather negative. NMR is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
NMR had positive earnings in the past year.
NMR had a negative operating cash flow in the past year.
Of the past 5 years NMR 4 years were profitable.
NMR had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
NMR has a worse Return On Assets (0.24%) than 76.47% of its industry peers.
With a Return On Equity value of 4.04%, NMR is not doing good in the industry: 65.69% of the companies in the same industry are doing better.
Looking at the Return On Invested Capital, with a value of 0.26%, NMR is doing worse than 82.84% of the companies in the same industry.
NMR had an Average Return On Invested Capital over the past 3 years of 0.32%. This is significantly below the industry average of 9.53%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.24% | ||
| ROE | 4.04% | ||
| ROIC | 0.26% |
ROA(3y)0.29%
ROA(5y)0.23%
ROE(3y)4.51%
ROE(5y)3.58%
ROIC(3y)0.32%
ROIC(5y)N/A
1.3 Margins
The Profit Margin of NMR (3.85%) is worse than 70.59% of its industry peers.
NMR's Profit Margin has declined in the last couple of years.
NMR's Operating Margin of 6.07% is on the low side compared to the rest of the industry. NMR is outperformed by 80.88% of its industry peers.
In the last couple of years the Operating Margin of NMR has declined.
Looking at the Gross Margin, with a value of 41.61%, NMR is doing worse than 66.67% of the companies in the same industry.
In the last couple of years the Gross Margin of NMR has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.07% | ||
| PM (TTM) | 3.85% | ||
| GM | 41.61% |
OM growth 3Y-22.1%
OM growth 5Y-18.42%
PM growth 3Y-30.5%
PM growth 5Y-19.62%
GM growth 3Y-6.62%
GM growth 5Y-6.68%
2. Health
2.1 Basic Checks
NMR has less shares outstanding than it did 1 year ago.
The number of shares outstanding for NMR has been reduced compared to 5 years ago.
The debt/assets ratio for NMR is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -0.36, we must say that NMR is in the distress zone and has some risk of bankruptcy.
NMR has a Altman-Z score of -0.36. This is amonst the worse of the industry: NMR underperforms 89.71% of its industry peers.
NMR has a Debt/Equity ratio of 10.69. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 10.69, NMR is not doing good in the industry: 90.69% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.69 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.36 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 0.20 indicates that NMR may have some problems paying its short term obligations.
NMR has a Current ratio of 0.20. This is amonst the worse of the industry: NMR underperforms 87.25% of its industry peers.
NMR has a Quick Ratio of 0.20. This is a bad value and indicates that NMR is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.20, NMR is doing worse than 87.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.2 | ||
| Quick Ratio | 0.2 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 24.60% over the past year.
Measured over the past years, NMR shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.34% on average per year.
Looking at the last year, NMR shows a very strong growth in Revenue. The Revenue has grown by 96.70%.
The Revenue has been growing slightly by 4.75% on average over the past years.
EPS 1Y (TTM)24.6%
EPS 3Y-23.06%
EPS 5Y-13.34%
EPS growth Q2Q108.8%
Revenue 1Y (TTM)96.7%
Revenue growth 3Y8.4%
Revenue growth 5Y4.75%
Revenue growth Q2Q89.7%
3.2 Future
NMR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.41% yearly.
Based on estimates for the next years, NMR will show a decrease in Revenue. The Revenue will decrease by -1.00% on average per year.
EPS Next Y58.74%
EPS Next 2Y34.74%
EPS Next 3Y25.41%
EPS Next 5YN/A
Revenue Next Year-5.67%
Revenue Next 2Y-2.12%
Revenue Next 3Y-1%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 13.02, which indicates a correct valuation of NMR.
NMR's Price/Earnings is on the same level as the industry average.
The average S&P500 Price/Earnings ratio is at 24.81. NMR is valued slightly cheaper when compared to this.
A Price/Forward Earnings ratio of 10.50 indicates a reasonable valuation of NMR.
NMR's Price/Forward Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 19.91, NMR is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.02 | ||
| Fwd PE | 10.5 |
4.2 Price Multiples
NMR's Enterprise Value to EBITDA ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 33.83 |
4.3 Compensation for Growth
NMR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NMR's earnings are expected to grow with 25.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.22
PEG (5Y)N/A
EPS Next 2Y34.74%
EPS Next 3Y25.41%
5. Dividend
5.1 Amount
NMR has a Yearly Dividend Yield of 3.29%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 8.08, NMR has a dividend in line with its industry peers.
NMR's Dividend Yield is a higher than the S&P500 average which is at 2.59.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.29% |
5.2 History
The dividend of NMR decreases each year by -1.28%.
NMR has been paying a dividend for at least 10 years, so it has a reliable track record.
NMR has decreased its dividend recently.
Dividend Growth(5Y)-1.28%
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
38.42% of the earnings are spent on dividend by NMR. This is a low number and sustainable payout ratio.
DP38.42%
EPS Next 2Y34.74%
EPS Next 3Y25.41%
NOMURA HOLDINGS INC-SPON ADR
NYSE:NMR (12/6/2023, 11:15:02 AM)
4.165
+0.08 (+2.08%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap12.56B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.29% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.02 | ||
| Fwd PE | 10.5 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.22
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.24% | ||
| ROE | 4.04% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 6.07% | ||
| PM (TTM) | 3.85% | ||
| GM | 41.61% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.69 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.2 | ||
| Quick Ratio | 0.2 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)24.6%
EPS 3Y-23.06%
EPS 5Y
EPS growth Q2Q
EPS Next Y58.74%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)96.7%
Revenue growth 3Y8.4%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y